Uptake rates of statins and angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensin receptor blockers (ARB) more than doubled for secondary prevention and the management of stable coronary artery disease (Table 5). This evidence concerns the gene ACE and coronary artery disorder.